← back to search

Jennifer L. Caswell‐Jin

Stanford Medicine · US
Area of research
Cancer Research · Genetics
Research interest
Research interests include Breast Cancer Treatment Studies, BRCA gene mutations in cancer, Global Cancer Incidence and Screening, and Advanced Breast Cancer Therapies.
h-index
24
citations
2,957
works
100
NIH funding
primary concept
Medicine
email

Recent publications

Development and Validation of a Simulation Model–Based Tool to Support Individualized Physical Activity Discussions and Prescriptions for Breast Cancer Survivors
JCO Clinical Cancer Informatics 2025cited by 4position: middledoi
Breast Cancer Risk Modification in Women with Pathogenic Variants in <i>BRCA1</i> , <i>BRCA2</i> , <i>ATM</i> , <i>CHEK2</i> , and <i>PALB2</i>
Cancer Research Communications 2025cited by 3position: middledoi
Characterization of breast tumors and the tumor immune landscape in young, diverse participants of the Northern California Breast Cancer Family Registry.
Journal of Clinical Oncology 2025cited by 0position: middledoi
Association of driving distance to clinic with treatment route and dosing for metastatic breast cancer.
Journal of Clinical Oncology 2025cited by 0position: middledoi
Analysis of Breast Cancer Mortality in the US—1975 to 2019
JAMA 2024cited by 261position: firstdoi
Collaborative Modeling to Compare Different Breast Cancer Screening Strategies
JAMA 2024cited by 51position: middledoi
Abstract P3-12-34: Antibiotic use and mortality from triple-negative breast cancer
Cancer Research 2022cited by 0position: middledoi
Spatial proteomic characterization of HER2-positive breast tumors through neoadjuvant therapy predicts response
Nature Cancer 2021cited by 86position: middledoi
Performance of the IBIS/Tyrer‐Cuzick model of breast cancer risk by race and ethnicity in the Women's Health Initiative
Cancer 2021cited by 53position: middledoi
Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07)
Nature Communications 2020cited by 66position: middledoi
Abstract P4-07-01: Tumor expression and microenvironment in HER2-positive breast cancer before and on HER2-targeted therapy: Analysis of microarray expression data from the TRIO-US B07 trial
Cancer Research 2020cited by 0position: firstdoi
Understanding patient perspectives on window of opportunity clinical trials.
Journal of Clinical Oncology 2020cited by 0position: lastdoi
Dynamics of breast-cancer relapse reveal late-recurring ER-positive genomic subgroups
Nature 2019cited by 447position: middledoi
Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapy
Nature Communications 2019cited by 61position: firstdoi
Chromatin regulators mediate anthracycline sensitivity in breast cancer
Nature Medicine 2019cited by 44position: middledoi
Publisher Correction: Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapy
Nature Communications 2019cited by 1position: firstdoi
Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients
Nature Communications 2015cited by 44position: middledoi
Genome-wide association study of breast cancer in Latinas identifies novel protective variants on 6q25
Nature Communications 2014cited by 148position: middledoi
Abstract LB-299: Genome wide association study of breast cancer in Latinas identifies protective variants of Indigenous American origin on 6q25
Cancer Research 2014cited by 1position: middledoi
Abstract 5078: Genome wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients
Cancer Research 2014cited by 0position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Christina Curtis · Stanford University9 papers (2019–2025)Allison W. Kurian · Stanford University6 papers (2021–2025)Katherine McNamara · Stanford University5 papers (2019–2021)Esther M. John · Palo Alto University5 papers (2014–2025)Michael F. Press · University of Southern California5 papers (2019–2021)Zhicheng Ma · Stanford Medicine4 papers (2019–2025)Carlos Caldas · Concern Foundation3 papers (2019–2019)Eran Kotler · Palo Alto University3 papers (2020–2021)Dennis J. Slamon · APLA Health3 papers (2020–2021)Suet‐Feung Chin · Cancer Research UK Cambridge Center3 papers (2019–2019)Jason J. Zoeller · Harvard Stem Cell Institute3 papers (2020–2021)Sara A. Hurvitz · University of Washington Applied Physics Laboratory3 papers (2020–2021)Elena Provenzano · Cambridge University Hospitals NHS Foundation Trust3 papers (2019–2019) · 2 papers (2020–2020)Johannes G. Reiter · University of the Incarnate Word2 papers (2019–2019)Debu Tripathy · The University of Texas MD Anderson Cancer Center2 papers (2019–2019)Alejandra Perez · University of Miami2 papers (2020–2020)Robert Dichmann · Central Coast Nephrology2 papers (2020–2020)Jie Ding · Palo Alto University2 papers (2019–2019)Amy Trentham‐Dietz · University of Wisconsin–Madison2 papers (2024–2025)